Sarcopenia Identification Using Alternative Vertebral Landmarks in Individuals with Lung Cancer.

Background: (1)Sarcopenia, or low skeletal mass index (SMI), contributes to higher lung cancer mortality. The SMI at third lumbar vertebrae (L3) is the reference standard for body composition analysis. However, there is a need to explore the validity of alternative landmarks in this population. We compared the agreement of sarcopenia identification at the first lumbar (L1) and second lumbar (L2) to L3 in non-Hispanic Black (NHB) and White (NHW) individuals with lung cancer. Methods: (2)This retrospective, cross-sectional study included 214 NHB and NHW adults with lung cancer. CT scans were analyzed to calculate the SMI at L1, L2, and L3. T-tests, chi-square, Pearson's correlation, Cohen's kappa, sensitivity, and specificity analysis were used. Results: (3)Subjects presented with a mean age of 68.4 ± 9.9 years and BMI of 26.3 ± 6.0 kg/m2. Sarcopenia prevalence varied from 19.6% at L1 to 39.7% at L3. Cohen's kappa coefficient was 0.46 for L1 and 0.64 for L2, indicating weak and moderate agreement for the identification of sarcopenia compared to L3. Conclusions: (4)Sarcopenia prevalence varied greatly depending on the vertebral landmark used for assessment. Using L2 or L1 alone resulted in a 16.8% and 23.8% misclassification of sarcopenia in this cohort of individuals with lung cancer.

Development of a Novel Circulating Autoantibody Biomarker Panel for the Identification of Patients with 'Actionable' Pulmonary Nodules.

Due to poor compliance and uptake of LDCT screening among high-risk populations, lung cancer is often diagnosed in advanced stages where treatment is rarely curative. Based upon the American College of Radiology's Lung Imaging and Reporting Data System (Lung-RADS) 80-90% of patients screened will have clinically "non-actionable" nodules (Lung-RADS 1 or 2), and those harboring larger, clinically "actionable" nodules (Lung-RADS 3 or 4) have a significantly greater risk of lung cancer. The development of a companion diagnostic method capable of identifying patients likely to have a clinically actionable nodule identified during LDCT is anticipated to improve accessibility and uptake of the paradigm and improve early detection rates. Using protein microarrays, we identified 501 circulating targets with differential immunoreactivities against cohorts characterized as possessing either actionable (n = 42) or non-actionable (n = 20) solid pulmonary nodules, per Lung-RADS guidelines. Quantitative assays were assembled on the Luminex platform for the 26 most promising targets. These assays were used to measure serum autoantibody levels in 841 patients, consisting of benign (BN; n = 101), early-stage non-small cell lung cancer (NSCLC; n = 245), other early-stage malignancies within the lung (n = 29), and individuals meeting United States Preventative Screening Task Force (USPSTF) screening inclusion criteria with both actionable (n = 87) and non-actionable radiologic findings (n = 379). These 841 patients were randomly split into three cohorts: Training, Validation 1, and Validation 2. Of the 26 candidate biomarkers tested, 17 differentiated patients with actionable nodules from those with non-actionable nodules. A random forest model consisting of six autoantibody (Annexin 2, DCD, MID1IP1, PNMA1, TAF10, ZNF696) biomarkers was developed to optimize our classification performance; it possessed a positive predictive value (PPV) of 61.4%/61.0% and negative predictive value (NPV) of 95.7%/83.9% against Validation cohorts 1 and 2, respectively. This panel may improve patient selection methods for lung cancer screening, serving to greatly reduce the futile screening rate while also improving accessibility to the paradigm for underserved populations.

Seventeen-electron chromium(i)tricarbonyltris(phosphine) complexes supported by tris(phosphinomethyl)phenylborates.

The inaugural crystallographic characterization of chromium(i)tricarbonyltris(phosphine) radicals has been achieved. Oxidation of [PPN][Cr(CO)3(PhBP)] (PhBP = [PhB(CH2PPh2)3]-) and analogous Cr(0) complexes featuring 3,5-dimethylphenyl and 3,5-bis(trifluoromethyl)phenyl borate substituents affords charge-neutral Cr(CO)3(PhBP) zwitterions, containing the first fully characterized [Cr(CO)3P3]+ units. The stabilization affected by the intramolecular charge separation established by PhBP ligands dramatically increases the robustness of these seventeen-electron Cr(i) complexes. Previous attempts to isolate salts of mer/fac-[Cr(CO)3P3]+ were frustrated by the thermal instability of these cations. The EPR spectroscopic data of Cr(CO)3(PhBP) supports Rieger's hypothesized low temperature preparation of fac-[Cr(CO)3{CH3C(CH2PPh2)3}]+. The robust [Cr(CO)3P3]+ unit of Cr(CO)3(PhBP) motivated the preparation of structurally characterized Cr(0)/Cr(i) (Cr(CO)3{η6-(PhBP)Cr(CO)3}, Cr(CO)3{η6-(((3,5-CH3)C6H3)BP)Cr(CO)3}) and W(0)/Cr(i) (W(CO)3{η6-(((3,5-CH3)C6H3)BP)Cr(CO)3}) complexes. While these bimetallics feature classical κ3-phosphine and η6-arene metal-binding, they are noteworthy since all other reported mixed-valent Cr(0)/Cr(i) complexes exhibit (a) significant thermal instability that has precluded their isolation and (b) greater uncertainty regarding the presence of distinct Cr(i) and Cr(0) centers. This work illustrates the utility of tris(phosphino)borates for the stabilization of cationic metal fragments within zwitterions that are inaccessible or difficult to characterize independently.

Inductive modulation of tris(phosphinomethyl)phenylborate donation at group VI metals via borate phenyl substituent modification.

A series of zerovalent group VI metal complexes of tris(diisopropylphosphinomethyl)phenylborate ([PhB(CH2PiPr2)3]-, PhBPiPr3), including [PPN][M(CO)3(PhBPiPr3)] (M = Cr, Mo, W) and the first bimetallics in which PhBPiPr3 serves as a bridging ligand via binding M(CO)3 units at the three phosphorus atoms and the borate phenyl substituent, have been synthesized and fully characterized. Two new tris(phosphinomethyl)borates featuring 3,5-dimethylphenyl and 3,5-bis(trifluoromethyl)phenyl borate substituents were prepared as crystallographically characterized thallium salts, and metallated giving their inaugural transition metal complexes [PPN][M(CO)3(((3,5-Me)C6H3)BPPh3)] and [PPN][M(CO)3(((3,5-CF3)C6H3)BPPh3)]. A comparative ν(CO) infrared spectroscopic analysis and examination of half wave potentials assessed by cyclic voltammetry supports a ligand donor ranking of Tp > PhBPiPr3 ≥ Cp > PhBPPh3 > triphos. For these anionic complexes, in which a lower electrostatic contribution to zerovalent metal-PhBPR3 binding is likely operative relative to that present in the zwitterionic complexes most commonly prepared with tris(phosphinomethyl)borates, PhBPR3 ligands do not function as strongly donating scorpionates. Nevertheless, PhBPPh3 is a substantially stronger donor than triphos towards zerovalent M(CO)3; the half wave potentials of [Et4N][M(CO)3(PhBPPh3)] are ∼340 mV lower than those of M(CO)3(triphos). The potentials of the ((3,5-Me)C6H3)BPPh3 group VI metal tricarbonyl anions are more negative than those of the corresponding ((3,5-CF3)C6H3)BPPh3 group VI metal tricarbonyl anions by ∼50 mV, suggesting a modest, yet rational, tuning of PhBPPh3 donation via inductive modulation of the borate anion charge.